After Expiry of the Voluntary Public Tender Offer Applied Biosystems Deutschland GmbH Holds approximately 73.8% of GENEART AG

Published: May 28, 2010

REGENSBURG, GERMANY--(Marketwire - May 28, 2010) -

Geneart AG / After Expiry of the Voluntary Public Tender Offer Applied Biosystems Deutschland GmbH Holds approximately 73.8% of GENEART AG processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.

Regensburg, May 28, 2010 - According to the announcement of Applied Biosystems Deutschland GmbH the German subsidiary of Life Technologies Corporation, a biotechnology company based in California/USA, holds approximately 73.8% of GENEART AG shares after the expiry of the voluntary tender offer from April 13, 2010.

For further inquiries, please contact:
Dr. Karoline Stürmer
Josef-Engert-Str. 11
93053 Regensburg
Phone: (0)941-942 76-417
Fax: (0)941-942 76-711

Frank Ostermair
Better Orange IR & HV AG
Haidelweg 48
81241 Munich
Phone: (0)89-8896906-10
Fax: (0)89-8896906-66

Legal Information:

This document may contain estimates, prognoses and opinions about company plans and objectives, products or services, future results, opinions about these results or opinions leading up to these results. All these projections into the future are subject to risk, uncertainty and unforeseeable change outside the control of the GENEART Group. Many factors may lead to actual results, which considerably deviate from the given projections for these results.


In 2000 GENEART entered the Gene Synthesis market and has since become the global market leader. Today, the company is one of the leading specialists in the Synthetic Biology field. Experts at GENEART provide key technologies for the development and production of new therapeutics and vaccines. Customers also take advantage of GENEART services to customize enzyme attributes, such as the attributes of enzymes used as detergent additives, and to construct bacteria, which produce complex biopolymers or break down polymers, such as synthetics, petroleum components, etc. GENEART's service portfolio ranges from the optimization and production of synthetic genes according to DIN EN ISO 9001:2008, to the generation of gene variants or complex gene libraries and the production of cell lines, to the development and production of DNA and protein based drug candidates. GENEART AG in Regensburg and its subsidiaries GENEART Inc. in Toronto (Canada) and GENEART Inc. in San Francisco (USA) employ about 180 people. The company is listed on the German Stock Exchange since May 2006. Since April 2010, the US-American Life Technologies Corporation, one of the leading biotechnology companies worldwide with 2009 revenues of USD 3.3B and about 9,000 employees, is majority shareholder of GENEART AG.

About Life Technologies Corporation:

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of USD 3.3B in 2009, employs approximately 9,000 people, has a presence in approximately 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit our website:


 --- End of Message ---

Geneart AG
Josef-Engert-Str.11 Regensburg Germany

Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Open Market (Freiverkehr) in Frankfurter Wertpapierbörse;

Press release (PDF):

Back to news